Pharmacokinetic evaluation of ambrisentan

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 3, 2011, Pages 371-380

  Buckley, Mitchell S ^a   Wicks, Laura M ^a   Staib, Robin L ^a   Kirejczyk, Anna K ^a   Varker, Andrew S ^a   Gibson, Jamie J ^b   Feldman, Jeremy P ^c  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^c Arizona Pulmonary Specialists Ltd   (United States)

Author keywords

ambrisentan; endothelin receptor antagonist; pulmonary arterial hypertension; pulmonary vasodilator

Indexed keywords

AMBRISENTAN; BOSENTAN; CYCLOSPORIN; DIGOXIN; ENDOTHELIN RECEPTOR ANTAGONIST; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ILOPROST; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; LU 208075; MACITENTAN; MOXIFLOXACIN; NORETHISTERONE; OMEPRAZOLE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; RIFAMPICIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNCLASSIFIED DRUG; UNIPROST; WARFARIN;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DOUBLE BLIND PROCEDURE; DOUBLE BLIND PROCEDURE (TOPIC); DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; NONHUMAN; NOSE CONGESTION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINGLE DRUG DOSE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION, PULMONARY; PHENYLPROPIONATES; PYRIDAZINES; TREATMENT OUTCOME;

EID: 79951898431     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.557181     Document Type: Article

References (54)

1. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:527-38
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36
3. DAlonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343-9
4. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-63 (Pubitemid 41632043)
5. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S (Pubitemid 38759713)
6. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:78-84
7. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur J Respir J 2008;31:407-15
8. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 2007;28:117-25 (Pubitemid 46330544)
9. Traiger GL. Pulmonary arterial hypertension. Crit Care Nurs Q 2007;30:20-41
10. Kirkby NS, Hadoke PWF, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153:1105-19 (Pubitemid 351415492)
11. Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drug 2010;11:1066-73
12. Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2007;3:887-900
13. Badesch DB, Abman SH, Simonnequ G, et al. Medical therapy of pulmonary arterial hypertension. Chest 2007;131:1917-28
14. Chanick RN, Simmoneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23 (Pubitemid 32971843)
15. Rubin, LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903 (Pubitemid 34984638)
16. Galie N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008;371:2093-100 (Pubitemid 351902178)
17. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54 (Pubitemid 44305274)
18. Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improved and maintained with bosentan. J Heart Lung Transplantation 2007;26:181-7 (Pubitemid 46136035)
19. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7 (Pubitemid 38187114)
20. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56
21. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome an survival. Chest 2008;134:775-82
22. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Eur Respir J 2005;25:244-9
23. Liu C, Chen J, Gao Y, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. Cochrane Database Syst Rev 2009;3:CD004434
24. Casserly B, Klinger JR. Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des Dev Ther 2008;2:265-80
25. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35 (Pubitemid 41040298)
26. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-19
27. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:1971-81
28. Blalock SE, Matulevicius S, Mitchell LC, et al. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail 2010;16:121-7
29. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-9
30. Cartin-ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension. Chest 2010. [Epub ahead of print]
31. Letairis (ambrisentan) package insert. Gilead Sciences, Inc., Foster City, CA; 2009 Aug. Accessed October 2010.
32. Rubin LJ, Dufton C, Gerber MJ. Ambrisentan for pulmonary arterial hypertension. Future Cardiol 2005;1:1-8
33. Price LC, Howard LS. Endothelin receptor antagonists in pulmonary arterial hypertension: rational and place in therapy. Am J Cardiovasc Drugs 2008;8:171-85 (Pubitemid 351812270)
34. Walker G, Mandagere A, Dufton C, Venitz J. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol 2009;67:527-34
35. Spence R, Mandagere A, Dufton C, Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmcol 2008;48:1451-9
36. Richards DB, Walker GA, Mandagere A, et al. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol 2009;49:719-24
37. Spence R, Mandagere A, Walker G, et al. Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study. Clin Drug Investig 2010;30:313-24
38. Croxtall JD, Keam SJ. Ambrisentan. Drugs 2008;68:2195-204
39. Hoeper MM. Drug therapy of pulmonary arterial hypertension: current and future agents. Drugs 2005;65:1337-54 (Pubitemid 41043890)
40. Croom KR, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 2008;68:383-97 (Pubitemid 351227349)
41. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57 (Pubitemid 41653106)
42. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30
43. Effects of the combination of bosentan and sildenafil versus sildenafil monotherapy on pulmonary arterial hypertension (PAH) (Compass 2). Available from: www.clinicaltrials.gov/ ct2/show/NCT00303459? term=bosentan&rank=9 [Last accessed 15 October 2010]
44. Simonneau G, Robbins IM, Geghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54
45. Kawut SM. Caring for the orphans orphan: treatment of patients with portopulmonary hypertension. Eur Respir J 2007;30:1038-40 (Pubitemid 351194747)
46. Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 2005;150:716
47. Ivy DD. Pharmacokinetics and safety of ambrisentan in pediatric patients with pulmonary arterial hypertension. Platform presentation at the American Thoracic Society International Conference, San Diego, CA; 2009
48. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATH-2. Eur Respir J 2004;24:353-9 (Pubitemid 39232254)
49. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63 (Pubitemid 44924827)
50. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4 (Pubitemid 46331988)
51. Red Book 2010: Pharmacys Fundamental Reference, 2010 edition. Thomson Reuters, Montvale (NJ); 2010
52. A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION). Available from: www.clinicaltrials.gov/ct2/show/ NCT01178073?term=ambition +study&rank=1 [Last accessed 15 October 2010]
53. Tracleer (bosentan) package insert. Actelion Pharmaceuticals US, Inc., South San Francisco, CA; 2009 Aug. Accessed October 2010.
54. Thelin (sitaxsentan) package insert. Pfizer Canada, Kirkland, Quebec, Canada; 2008 Nov. Accessed October 2010.